Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases and intranasal vaccines. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™); proprietary intranasal vaccines; and an immune modulating therapeutic for COVID-19 (T-COVID™).
Our management team has broad expertise across scientific and business operations, inventing compounds and advancing product candidates through clinical development.
Board of Directors
We believe strategic partnerships break barriers to innovation and we continuously evaluate partnership opportunities. Contact Jose Ochoa, Chief Business Officer, for partnership inquiries.
For partnership opportunities contact:
Chief Business Officer